Karyopharm Therapeutics Inc.

Michael Kauffman

Sharon Shacham

Vincent Premaratna Sandanayaka

Sharon Shechter

Dilara McCauley

William Senapedis

Yosef Landesman

Jean-Richard Saint-Martin

Dilârâ McCauley

Vincent P Sandanyaka

Vincent P Sandanayaka

The invention generally relates to the field of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to new substituted-heterocyclic azole compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, pulmonary fibrosis, hepatic fibrosis, glomerulonephritis, and other renal disorders, and for the treatment of viral infections (both acute and chronic).

Nuclear transport modulators and uses thereof

The invention generally relates to nuclear transport modulators, e.g CRM1 inhibitors, and more particularly to a compound represented by formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula (I), or a pharmaceutically acceptable salt or composition thereof, e.g, in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity. 

Growing community of inventors

Newton, MA, United States of America

Michael Kauffman